title: Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: a pilot study.
abstract: BACKGROUND
  Patients undergoing pertrochanteric hip fracture (PHF) repair surgery often receive perioperative allogeneic blood transfusions (ABTs) to avoid the deleterious effects of anemia. Nevertheless, concerns about adverse effects of ABTs have prompted the review of transfusion practice and the search for a safer treatment of perioperative anemia.
  
  
  METHODS
  The effect of preoperative 200 to 300 mg of intravenous (IV; Group 2; n = 55) iron sucrose administration on transfusion requirements and postoperative morbidity-mortality in patients with PHF has been prospectively investigated. A previous series of 102 PHF patients served as the control group (Group 1). All patients were older than 65 years and were operated on at the third day after admission to the hospital, by the same medical team and with the same implant.
  
  
  RESULTS
  Iron sucrose was well tolerated and reduced the transfusion rate in patients with admission hemoglobin levels of greater than 120 g per L (p < 0.05) who also received fewer units of red blood cells (p < 0.05). In addition, iron sucrose reduced postoperative infection rate (p < 0.05), but not 30-day mortality rate or mean length of hospital stay.
  
  
  CONCLUSIONS
  The administration of IV iron sucrose seems to reduce ABT requirements in patients with PHF and is associated to lower postoperative morbidity. The possible mechanisms involved in these effects are discussed.
authors.affiliation: Department of Orthopedic and Trauma Surgery, Miguel Servet University Hospital, Zaragoza, Spain.
authors.forename: Jorge
authors.initials: J
authors.lastname: Cuenca
authors.forename: José A
authors.initials: JA
authors.lastname: García-Erce
authors.forename: Manuel
authors.initials: M
authors.lastname: Muñoz
authors.forename: Mónica
authors.initials: M
authors.lastname: Izuel
authors.forename: Angel A
authors.initials: AA
authors.lastname: Martínez
authors.forename: Antorio
authors.initials: A
authors.lastname: Herrera
mesh_terms: D000368:Aged; D003428:Cross Infection / Q000209:etiology / Q000517:prevention & control; D017707:Erythrocyte Transfusion / Q000706:statistics & numerical data; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D006620:Hip Fractures / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D006801:Humans; D007262:Infusions, Intravenous; D007501:Iron / Q000008:administration & dosage*; D007902:Length of Stay; D008297:Male; D019637:Orthopedic Procedures; D010865:Pilot Projects; D011183:Postoperative Complications / Q000517:prevention & control; D011300:Preoperative Care / Q000379:methods*
chemical_list: D005290:Ferric Compounds; D007501:Iron; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid